Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 585-590

  Tauchi, Tetsuzo ^a   Kizaki, Masahiro ^b   Okamoto, Shinichiro ^c   Tanaka, Hideo ^d   Tanimoto, Mitsune ^e   Inokuchi, Koiti ^f   Murayama, Tohru ^g   Saburi, Yoshio ^h   Hino, Masayuki ⁱ   Tsudo, Mitsuru ^j   Shimomura, Taizo ^k   Isobe, Yasushi ^l   Oshimi, Kazuo ^l   Dan, Kazuo ^a   Ohyashiki, Kazuma ^a   Ikeda, Yasuo ^m  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g HYOGO CANCER CENTER   (Japan)

^h OITA PREFECTURAL HOSPITAL   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j OSAKA RED CROSS HOSPITAL   (Japan)

^k NTT Kyushu General Hospital   (Japan)

^l JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m WASEDA UNIVERSITY   (Japan)

more..

Author keywords

BCR ABL; Chronic myelogenous leukemia; Imatinib

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; EDEMA; EVENT FREE SURVIVAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; INTERNET; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ONLINE SYSTEMS; PIPERAZINES; PYRIMIDINES; REGISTRIES; TIME FACTORS; YOUNG ADULT;

EID: 79954592021     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.027     Document Type: Article

References (16)

1. Kizaki M., Okamoto S., Tauchi T., Tanaka H., Tanimoto M., Inokuchi K., et al. Current and future perspectives on the TARGET system: the registration system for Glivec established by JSH. Int J Hematol 2008, 88(4):409-417.
2. Begg C.B., Engstrom P. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol 1987, 5:962-968.
3. George S. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 1996, 14:1364-1370.
4. Cassileth B.R. Clinical trials: time for action. J Clin Oncol 2003, 21:765-766.
5. Wright J.R., Bouma S., Dayes I., Sussman J., Simunovic M.R., Levine M.N., et al. The importance of reporting patient requirement details in phase III trials. J Clin Oncol 2006, 24:843-845.
6. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
7. Hughes T., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
8. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann I., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
9. Hochhaus A., O'Brien S., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
10. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.C., Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006, 12:1181-1184.
11. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571. Blood 2002, 99:319-325.
12. Michor F., Hughes T.P., Iwasa Y., Bransford S., Shah N.P., Sawyers C.L., et al. Dynamics of chronic myeloid leukemia. Nature 2005, 435:1267-1270.
13. Mahon F.X., Huguet F., Guilhot F., Rigual-Huguet F, Maloisel F., Rousselot P., et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from multicenter <>(STIM) study. Blood 2008, 112. 76a.
14. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
15. Atallah E., Durand J.B., Kantarjian H., Cortes J. Congestive heart failure is a rare event in patients recieving imatinib therapy. Blood 2007, 110:12233-21237.
16. Hatifeld A., Owen S., Pilot P.R. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007, 13:15-16.